ART first-line failure
Showing 1 - 25 of >10,000
Virologic Failure and Drug Resistance at and After Switching to
Active, not recruiting
- Hiv
- +2 more
-
Lilongwe, Malawi
- +1 more
Feb 14, 2022
HIV/AIDS Trial in Lesotho (switch)
Completed
- HIV/AIDS
- switch
-
Hlotse, Leribe, Lesotho
- +7 more
Mar 20, 2022
Large Scale Transition toDolutegravir-based First-line ART in
Not yet recruiting
- HIV Infections
-
Abidjan, Côte D'Ivoire
- +2 more
Mar 28, 2022
Chronic Disease Trial (Training in the A-DIVA scale and its failure prediction score)
Not yet recruiting
- Chronic Disease
- Training in the A-DIVA scale and its failure prediction score
- (no location specified)
Oct 2, 2023
HIV-1-infection Trial in Johannesburg (Doravirine/Lamivudine/Tenofovir)
Recruiting
- HIV-1-infection
-
Johannesburg, Gauteng, South Africa
- +2 more
Jun 6, 2022
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint
Active, not recruiting
- Recurrent Nasopharyngeal Carcinoma
- +2 more
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
-
Guangzhou, Guangdong, ChinaYanqun Xiang
Sep 5, 2022
Schizophrenia and Related Disorders, MDD, Bipolar Depression Trial (Clozapine, Esketamine Nasal Product, Escitalopram)
Not yet recruiting
- Schizophrenia and Related Disorders
- +2 more
- Clozapine
- +11 more
- (no location specified)
Jan 12, 2023
HIV, AIDS Trial in Durban, Mbarara (HIV-1 RNA Resistance Testing)
Completed
- HIV
- AIDS
- HIV-1 RNA Resistance Testing
-
Durban, South Africa
- +1 more
Mar 28, 2022
Schizophrenia and Related Disorders, Early Treatment-Resistance Trial in Worldwide (Clozapine, Second-line Antipsychotics
Not yet recruiting
- Schizophrenia and Related Disorders
- Early Treatment-Resistance
- Clozapine
- Second-line Antipsychotics (treatment as usual)
-
Innsbruck, Austria
- +12 more
Jul 27, 2023
HIV Trial in Kumasi (Virological monitoring)
Active, not recruiting
- HIV
- Virological monitoring
-
Kumasi, GhanaKomfo Anokye Teaching Hospital
Jul 28, 2021
MDD, Treatment Resistant Depression Trial in Worldwide (Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine HCl)
Not yet recruiting
- Major Depressive Disorder
- Treatment Resistant Depression
- Esketamine Nasal Product
- +3 more
-
Innsbruck, Austria
- +12 more
Jul 25, 2023
Soft Tissue Sarcomas Trial in Zhengzhou (Anlotinib Hydrochloride)
Completed
- Soft Tissue Sarcomas
- Anlotinib Hydrochloride
-
Zhengzhou, Henan, ChinaAffiliated Cancer Hospital of Zhengzhou University&Henan Cancer
Mar 14, 2022
PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)
Recruiting
- PD-1 Inhibitor
- G-CSF
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022
Hepatocellular Carcinoma Trial (Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib)
Not yet recruiting
- Hepatocellular Carcinoma
- Hepatic Artery Infusion Chemotherapy
- +3 more
- (no location specified)
Feb 7, 2022
Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)
Recruiting
- Classic Hodgkin's Lymphoma
- Sintilimab
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022
Esophageal Cancer Trial in Hat yai (BKM120)
Terminated
- Esophageal Cancer
-
Hat yai, Songkhla, ThailandSongklanagarind Hospital, Prince of Songkla University
Oct 3, 2021
T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;
Not yet recruiting
- T-cell Lymphoma Patients After First-line Treatment Failure
- SHR2554; Chidamide analog tablets
- SHR2554 analog tablets; Chidamide
- (no location specified)
Nov 5, 2023
Depression, Depressive Disorder, Depressive Disorder, Major Trial in France (microbiotherapy (GynMDD), )
Recruiting
- Depression
- +2 more
- microbiotherapy (GynMDD)
- placebo
-
Besançon, France
- +3 more
Sep 8, 2022
Pancreas Cancer Trial in New York (Pembrolizumab, Azacitidine)
Active, not recruiting
- Pancreas Cancer
-
New York, New YorkColumbia University Irving Medical Center
Nov 29, 2022
OTTAPE : Observatory on Use of New Therapies in Treatment of
Active, not recruiting
- Pelvic-perineal Pathology
- None. This is a non-interventional observational study.
-
Nîmes, FranceCHU Nimes
Feb 3, 2022
HER2 Insertion Mutation Positive Advanced NSCLC Trial in Changsha (PD-1 Combined With Pyrotinib)
Recruiting
- HER2 Insertion Mutation Positive Advanced NSCLC
- PD-1 Combined With Pyrotinib
-
Changsha, Hunan, ChinaHunan Provincal Tumor Hospital
Mar 1, 2022
Respiratory Failure, Hypoxemic Respiratory Failure Trial in Rome (Noninvasive respiratory support)
Recruiting
- Respiratory Failure
- Hypoxemic Respiratory Failure
- Noninvasive respiratory support
-
Rome, ItalyGemelli
Apr 27, 2022
Option B+: Study on Safety, Viral Suppression, and Survival on
Completed
- HIV
- Infant Exposure to Efavirenz
-
Lilongwe, MalawiUNC Project Malawi
Mar 10, 2021